Dupilumab
Itch, urticaria activity improve with dupilumab after refractory antihistamine treatment
SAN DIEGO — Patients with chronic spontaneous urticaria that was not controlled with H1 antihistamines experienced improvements in itch and urticaria activity with dupilumab, according to a poster presented here.
Dupilumab improves lichenification in atopic dermatitis across age, racial groups
Dupilumab rapidly treated and maintained improvements in lichenification, a type of skin thickening from repetitive scratching, among patients of varying ages and races with atopic dermatitis, according to a study.
Adherence to asthma biologics varies by therapy given, tends to be low
SAN DIEGO — Across six asthma biologics, adherence differed by the therapy given and was often low or irregular based on three adherence measures, according to a presentation here.
Eosinophilic esophagitis improves with dupilumab regardless of food elimination diets
SAN DIEGO — Adolescents and adults with eosinophilic esophagitis improved with dupilumab regardless of whether they were practicing food elimination diets during treatment, according to a poster presented here.
Baseline factors impact odds for clinical remission with dupilumab in asthma
SAN DIEGO — Researchers found increased odds for clinical remission on dupilumab with high blood eosinophil and fractional exhaled nitric oxide levels in a moderate to severe asthma cohort, according to a poster presented here.
Dupilumab linked to reduced risks for psychiatric disorders in atopic dermatitis
Patients with dupilumab prescriptions for their atopic dermatitis had lower risks for psychiatric and sleep disorders than those prescribed other treatments, according to a study published in Annals of Allergy, Asthma & Immunology.
Dupilumab does not desensitize children with peanut allergy
Following receipt of dupilumab for 24 weeks, desensitization to peanut exposure in most children/adolescents with peanut allergy was not achieved, according to results published in Allergy.
Response to biologics may vary for patients with asthma, obesity
BOSTON — Patients with obesity and asthma may see reductions in exacerbations with biologic treatment, according to a presentation at the CHEST Annual Meeting.
Dupilumab associated with significantly lower malignancy risks in atopic dermatitis
Patients who used dupilumab for atopic dermatitis had significantly lower risks for internal malignancies than patients using other therapies, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.
Dupilumab outperforms other biologics in severe asthma treatment
Dupilumab was more effective than omalizumab, benralizumab and mepolizumab in treating patients with severe asthma, according to a pair of abstracts presented at European Respiratory International Congress.